Stock Taper
SCREENER COMPARE ANY 2 STOCKS
KZIA
KAZIA THERAPEUTICS LTD ADR
NASDAQ
$12.01
▼ DOWN 2.44% (-0.30)

KEY STATISTICS

Market Cap$19.59 M
52w High$17.40
52w Low$4.86
Dividend Yield—
Frequency—
P/E-2.52
Volume158.67K
Shares Out.1.62M

COMPANY

LEADERSHIP

John Edwin Friend
CHIEF EXECUTIVE
John Edwin Friend

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 6, 1999
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
6

PRICE TARGET

Target High$40.00
Target Low$25.00
Target Median$30.50
Target Consensus$31.50

UPCOMING EARNINGS

DateMar 2, 2027
DayTuesday
Rev. Est.—
MAR
2
TUE

SPLIT RECORD

DATETYPERATIO
2025-04-17Reverse1:5
2025-03-21Reverse1:5
2024-10-28Reverse1:10
2020-10-02Forward1041:1000
2017-07-14Reverse1:4
2013-01-28Forward1519:500
2012-01-03Reverse1:5

PRICE

$12.01 ▼ DOWN 2.44% (−$0.30)
OVERLAYS
$12.00$12.20$12.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM12.01

About Kazia Therapeutics Ltd ADR

https://www.kaziatherapeutics.com ↗

Kazia Therapeutics Limited, an Australian biotech specializing in oncology, develops anti-cancer drugs like Paxalisib for glioblastoma and EVT801 for various cancers.

INDUSTRY

Biotechnology

A PRODUCT KAZIA THERAPEUTICS LTD ADR IS KNOWN FOR

Paxalisib
Paxalisib

Paxalisib is an investigational brain-penetrant PI3K/Akt/mTOR inhibitor developed by Kazia for glioblastoma, currently in advanced clinical trials targeting newly diagnosed cases.

COMPETITORS

COMPETITOR
CNSP COMPARE
KPTI COMPARE
MBRX COMPARE

Revenue by Products

IconPRODUCTFY2021FY2024FY2025
Licensing Revenue$15.18M $2.3M ▼$0 ▼

Revenue by Geography

MapREGIONFY2021FY2025
CHINA$10.01M —
Swedan$5.18M —
ISRAEL— $42K

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
APIE
0.00% · 3.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
0.01%
HOLDERS
1
TOP 1 OF 1 · RANKED BY POSITION SIZE
Cordasco Financial Network
125 sh · $1K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR
Coffey Steven R. S.
Purchase · 100.0K shares
2026-01-08
★
OFFICER: CHIEF EXECUTIVE OFFICER
Friend John E. II
Purchase · 500.0K shares
2026-01-08
★
OFFICER: CHIEF EXECUTIVE OFFICER
Friend John E. II
Sale · 150.0K shares
2026-01-08
★
OFFICER: VP, FINANCE AND CONTROLLER
Bonacorda Jeffrey
Purchase · 150.0K shares
2026-01-08

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
3 GRADES IN THE LAST 12 MONTHS
BTIG BUY HC Wainwright & Co. BUY Maxim Group BUY

SECTORS PEERS

PEERPRICE
CNSP$5.77COMPARE
SNGX$0.38COMPARE
SILO$2.30COMPARE
INM$1.37COMPARE
CMND$1.05COMPARE
BDRX$0.87COMPARE
GRI$2.01COMPARE